Antigen Test Evaluated for Blastomycosis
By LabMedica International staff writers Posted on 15 Feb 2011 |
A commercially available assay for detection of Blastomyces dermatitidis antigen has been modified to permit quantitation in subjects with newly diagnosed blastomycosis.
An sandwich enzyme immunoassay (EIA) is available that will detect the antigen of the pathogenic mycoses B. dermatitidis in patients' serum, urine, cerebral spinal fluid, and other sterile body fluids.
In a study carried out at the University of Arkansas for Medical Sciences (Little Rock, AR, USA), samples were assayed from patients with newly diagnosed blastomycosis. Specimens from 27 subjects were analyzed and urine specimens from 25 healthy subjects and 25 subjects with conditions other than histoplasmosis or blastomycosis were analyzed to provide negative controls. If no antigen was detectable, the urine specimen was concentrated 10-fold and reanalyzed. Serum specimens were tested before and after treatment with ethylenediaminetetraacetic acid (EDTA) to dissociate immune complexes. Treatment of specimens with EDTA has not been shown to cause false-positive results in another fungal assay.
The assay used was the Mvista Blastomyces dermatitidis Antigen EIA, (MiraVista Diagnostics, Indianapolis, IN, USA). Of 27 patients, 23 (85.1%) had detectable B. dermatitidis antigen detected in their urine samples with a median of a 1.49 ng/mL, with a range of 0.21 ng/mL - 16.90 ng/mL. In two of these 23, positive results were obtained only after concentration of the urine specimen. Nine of 11 (81.8%) subjects had detectable B. dermatitidis antigen in their serum, including three subjects with negative results before treatment of serum with EDTA and positive results after EDTA treatment. B. dermatitidis antigen was not detected in specimens from 50 control subjects, but was detected in 15 patients with histoplasmosis. The authors concluded that the B. dermatitidis antigen was detected in most of the patients with blastomycosis and that it can be a useful tool for timely diagnosis. The study was published in February 2011, in the journal Diagnostic Microbiology and Infectious Disease.
Blastomycosis is an infection caused by inhaling microscopic spores produced by the fungus B. dermatitidis. Blastomycosis may be limited to the lungs or also involve the skin and bones. In its most severe form, the infection can spread throughout the body and become systemic. The fungus that causes the disease is found in moist soil and wood in the southeastern US, the Mississippi River valley, southern Canada, and Central America.
Related Links:
University of Arkansas for Medical Sciences
MiraVista Diagnostics
An sandwich enzyme immunoassay (EIA) is available that will detect the antigen of the pathogenic mycoses B. dermatitidis in patients' serum, urine, cerebral spinal fluid, and other sterile body fluids.
In a study carried out at the University of Arkansas for Medical Sciences (Little Rock, AR, USA), samples were assayed from patients with newly diagnosed blastomycosis. Specimens from 27 subjects were analyzed and urine specimens from 25 healthy subjects and 25 subjects with conditions other than histoplasmosis or blastomycosis were analyzed to provide negative controls. If no antigen was detectable, the urine specimen was concentrated 10-fold and reanalyzed. Serum specimens were tested before and after treatment with ethylenediaminetetraacetic acid (EDTA) to dissociate immune complexes. Treatment of specimens with EDTA has not been shown to cause false-positive results in another fungal assay.
The assay used was the Mvista Blastomyces dermatitidis Antigen EIA, (MiraVista Diagnostics, Indianapolis, IN, USA). Of 27 patients, 23 (85.1%) had detectable B. dermatitidis antigen detected in their urine samples with a median of a 1.49 ng/mL, with a range of 0.21 ng/mL - 16.90 ng/mL. In two of these 23, positive results were obtained only after concentration of the urine specimen. Nine of 11 (81.8%) subjects had detectable B. dermatitidis antigen in their serum, including three subjects with negative results before treatment of serum with EDTA and positive results after EDTA treatment. B. dermatitidis antigen was not detected in specimens from 50 control subjects, but was detected in 15 patients with histoplasmosis. The authors concluded that the B. dermatitidis antigen was detected in most of the patients with blastomycosis and that it can be a useful tool for timely diagnosis. The study was published in February 2011, in the journal Diagnostic Microbiology and Infectious Disease.
Blastomycosis is an infection caused by inhaling microscopic spores produced by the fungus B. dermatitidis. Blastomycosis may be limited to the lungs or also involve the skin and bones. In its most severe form, the infection can spread throughout the body and become systemic. The fungus that causes the disease is found in moist soil and wood in the southeastern US, the Mississippi River valley, southern Canada, and Central America.
Related Links:
University of Arkansas for Medical Sciences
MiraVista Diagnostics
Latest Microbiology News
- Handheld Device Delivers Low-Cost TB Results in Less Than One Hour
- New AI-Based Method Improves Diagnosis of Drug-Resistant Infections
- Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours
- Innovative ID/AST System to Help Diagnose Infectious Diseases and Combat AMR
- Gastrointestinal Panel Delivers Rapid Detection of Five Common Bacterial Pathogens for Outpatient Use
- Rapid PCR Testing in ICU Improves Antibiotic Stewardship
- Unique Genetic Signature Predicts Drug Resistance in Bacteria
- Unique Barcoding System Tracks Pneumonia-Causing Bacteria as They Infect Blood Stream
- Rapid Sepsis Diagnostic Test Demonstrates Improved Patient Care and Cost Savings in Hospital Application
- Rapid Diagnostic System to Detect Neonatal Sepsis Within Hours
- Novel Test to Diagnose Bacterial Pneumonia Directly from Whole Blood
- Interferon-γ Release Assay Effective in Patients with COPD Complicated with Pulmonary Tuberculosis
- New Point of Care Tests to Help Reduce Overuse of Antibiotics
- 30-Minute Sepsis Test Differentiates Bacterial Infections, Viral Infections, and Noninfectious Disease
- CRISPR-TB Blood Test to Enable Early Disease Diagnosis and Public Screening
- Syndromic Panel Provides Fast Answers for Outpatient Diagnosis of Gastrointestinal Conditions
Channels
Clinical Chemistry
view channel
‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection
Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more
Low-Cost Portable Screening Test to Transform Kidney Disease Detection
Millions of individuals suffer from kidney disease, which often remains undiagnosed until it has reached a critical stage. This silent epidemic not only diminishes the quality of life for those affected... Read more
New Method Uses Pulsed Infrared Light to Find Cancer's 'Fingerprints' In Blood Plasma
Cancer diagnoses have traditionally relied on invasive or time-consuming procedures like tissue biopsies. Now, new research published in ACS Central Science introduces a method that utilizes pulsed infrared... Read moreMolecular Diagnostics
view channel
Blood Test Could Predict Relapse of Autoimmune Blood Vessel Disease
Neutrophils, once believed to be uniform in nature, have been discovered to exhibit significant diversity. These immune cells, which play a crucial role in fighting infections, are also implicated in autoimmune... Read more
First-of-its-Kind Blood Test Detects Trauma-Related Diseases
In today’s fast-paced world, stress and trauma have unfortunately become common experiences for many individuals. Continuous exposure to stress hormones can confuse the immune system, causing it to misinterpret... Read moreHematology
view channel
New Scoring System Predicts Risk of Developing Cancer from Common Blood Disorder
Clonal cytopenia of undetermined significance (CCUS) is a blood disorder commonly found in older adults, characterized by mutations in blood cells and a low blood count, but without any obvious cause or... Read more
Non-Invasive Prenatal Test for Fetal RhD Status Demonstrates 100% Accuracy
In the United States, approximately 15% of pregnant individuals are RhD-negative. However, in about 40% of these cases, the fetus is also RhD-negative, making the administration of RhoGAM unnecessary.... Read moreImmunology
view channel
Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer
Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more
Machine Learning-Enabled Blood Test Predicts Immunotherapy Response in Lymphoma Patients
Chimeric antigen receptor (CAR) T-cell therapy has emerged as one of the most promising recent developments in the treatment of blood cancers. However, over half of non-Hodgkin lymphoma (NHL) patients... Read morePathology
view channel
Breakthrough Diagnostic Approach to Significantly Improve TB Detection
Tuberculosis (TB) remains the deadliest infectious disease globally, with 10.8 million new cases and 1.25 million deaths reported in 2023. Early detection through effective screening is crucial in identifying... Read more
Rapid, Ultra-Sensitive, PCR-Free Detection Method Makes Genetic Analysis More Accessible
Genetic testing has been an important method for detecting infectious diseases, diagnosing early-stage cancer, ensuring food safety, and analyzing environmental DNA. For a long time, polymerase chain reaction... Read moreTechnology
view channel
Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples
As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more
Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples
Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read more
Innovative, Label-Free Ratiometric Fluorosensor Enables More Sensitive Viral RNA Detection
Viruses present a major global health risk, as demonstrated by recent pandemics, making early detection and identification essential for preventing new outbreaks. While traditional detection methods are... Read moreIndustry
view channel
Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions
Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Grifols and Tecan’s IBL Collaborate on Advanced Biomarker Panels
Grifols (Barcelona, Spain), one of the world’s leading producers of plasma-derived medicines and innovative diagnostic solutions, is expanding its offer in clinical diagnostics through a strategic partnership... Read more